Pre-clinical companies

Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, melanoma, multiple myeloma, heart attacks and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.